Tongli Pharmaceuticals (USA), Inc. (TGLP/TGLP.OB) Wrap Up:

Tongli Pharmaceuticals (USA), Inc., through its subsidiary, Harbin Tianmu Pharmaceuticals Co., Ltd., develops, produces, and sells various pharmaceuticals and healthcare products based on traditional Chinese medicine in the People?s Republic of China. The company?s products include antihyperlipidemics, which are tablets to reduce cholesterol levels and soften blood vessels in order to improve circulation; Yuxiang anti-bacterial mouthwash; calcium gluconate oral liquid, a calcium supplement that is used for the prevention and treatment of diseases caused by calcium deficiency, such as osteoporosis, bone hypoplasis, and rickets; and leucorrhea relief tablet to reduce leucorrhea, a vaginal discharge. Its products also comprise arrhythmia relief tablet to treat atrioventricular premature beat; artery cleansing oral liquid, which is used in treatment of anoxemic cardiovascular and cerebrovascular disease, as well as hypertension and arteriosclerosis; Panax and Radix Polygoni capsule to reduce the symptoms of neurasthenia caused by mental or physical fatigue; and broad-spectrum disinfectant for use in the prevention of communicable diseases, such as Hepatitis B, bird flu, and severe acute respiratory syndrome. It sells its products through direct sales personnel and distributors to drug stores and hospitals. The company was formerly known as American Tony Pharmaceutical, Inc. and changed its name to Tongli Pharmaceuticals (USA), Inc. in October 2008. The company was founded in 1999 and is based in New York, New York.